Cita APA

Harrington, K., Kitano, S., Parkes, E., Moreno, I., Alonso-Casal, G., & Gambardella, V. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.

Citación estilo Chicago

Harrington, Kevin, Shigehisa Kitano, Eileen Parkes, Irene Moreno, Guzman Alonso-Casal, y Valentina Gambardella. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients With Advanced Solid Tumors. 2025.

Cita MLA

Harrington, Kevin, et al. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients With Advanced Solid Tumors. 2025.